Want to see ATHE full AI Analyst Report?
Top Page
Alterity Therapeutics
(NASDAQ:ATHE)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.50
▼(-44.07% Downside)
Action:Reiterated
Date:10/09/26
ATHE scores low primarily due to weak operating performance and cash burn (revenue dropped to $0 in FY2026 with widening losses), alongside bearish technical momentum (price below key moving averages and negative MACD). A low-debt balance sheet provides some support, but valuation remains constrained by ongoing losses and lack of dividend yield.
Positive Factors
Regulatory pathway
FDA alignment materially reduces regulatory uncertainty for ATH434 by clarifying the pivotal development route. A defined Phase 3 strategy can improve trial planning, capital allocation, and partnership credibility as Alterity advances its lead program toward potential approval.
Negative Factors
No current revenue
The collapse to zero revenue confirms that Alterity remains dependent on development financing rather than recurring commercial earnings. Large net losses reduce internal funding capacity and make progress toward a successful product launch essential to establishing a durable business model.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory pathway
FDA alignment materially reduces regulatory uncertainty for ATH434 by clarifying the pivotal development route. A defined Phase 3 strategy can improve trial planning, capital allocation, and partnership credibility as Alterity advances its lead program toward potential approval.
Read all positive factors
Alterity Therapeutics (ATHE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$43.42M
Dividend YieldN/A
Average Volume (3M)24.65K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue GrowthN/A
EPS Growth96.65%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.32
Shares Outstanding19,095,903
10 Day Avg. Volume31,323
30 Day Avg. Volume24,646
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)3.19
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-169.25
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$13.67Price Target Upside205.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$1.53M
Alterity Therapeutics Business Overview & Revenue Model
Company Description
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent e...
How the Company Makes Money
null...
Alterity Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 5.44M | 4.02M | 3.92M | 5.12M |
| Gross Profit | -113.01K | 5.31M | 3.80M | 3.63M | 4.76M |
| EBITDA | -27.69M | -14.52M | -19.46M | -14.53M | -17.39M |
| Net Income | -22.89M | -12.15M | -19.12M | -13.81M | -12.85M |
Balance Sheet | |||||
| Total Assets | 46.02M | 46.03M | 19.22M | 27.32M | 41.36M |
| Cash, Cash Equivalents and Short-Term Investments | 37.32M | 40.66M | 12.64M | 15.77M | 34.81M |
| Total Debt | 193.47K | 155.46K | 159.04K | 210.38K | 117.49K |
| Total Liabilities | 3.29M | 3.62M | 5.43M | 4.50M | 5.89M |
| Stockholders Equity | 42.73M | 42.40M | 13.80M | 22.81M | 35.47M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -11.45M | -12.61M | -20.04M | -12.43M |
| Operating Cash Flow | -22.03M | -11.45M | -12.61M | -20.04M | -12.34M |
| Investing Cash Flow | 7.34M | -7.50M | -5.72K | -36.46K | -89.15K |
| Financing Cash Flow | 18.71M | 39.67M | 9.22M | 124.34K | 16.30M |
Alterity Therapeutics Technical Analysis
Negative
4.47
Price Trends
3.85
Negative
4.29
Negative
4.02
Negative
Market Momentum
-0.41
Positive
22.81
Positive
5.66
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATHE, the sentiment is Negative. The current price of 4.47 is above the 20-day moving average (MA) of 3.12, above the 50-day MA of 3.85, and above the 200-day MA of 4.02, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 22.81 is Positive, neither overbought nor oversold. The STOCH value of 5.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATHE.
Alterity Therapeutics Risk Analysis
Alterity Therapeutics disclosed 44 risk factors in its most recent earnings report. Alterity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alterity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $27.26M | -0.63 | -202.14% | ― | ― | 73.69% | |
45 Neutral | $44.12M | -1.00 | -71.71% | ― | ― | 73.44% | |
45 Neutral | $105.85M | -2.31 | -88.81% | ― | ― | 43.63% | |
43 Neutral | $43.42M | -2.31 | -48.25% | ― | ― | 96.65% |
* Healthcare Sector Average
ATHE
Alterity Therapeutics
2.39
-2.21
-48.04%
CVM
Cel-Sci
1.62
-7.37
-81.98%
XBIT
XBiotech
1.99
-0.47
-19.11%
KLRS
Kalaris Therapeutics
2.02
-2.87
-58.69%
UNCY
Unicycive Therapeutics
3.87
-0.99
-20.37%
Alterity Therapeutics Corporate Events
Alterity Therapeutics CEO to Highlight MSA Program at Craig-Hallum Biotech Catalyst Conference
Oct 19, 2026
Alterity Therapeutics announced on October 19, 2026 that Chief Executive Officer David Stamler, M.D., will participate in a fireside chat at the Craig-Hallum Virtual Biotech Catalyst Conference on October 22, 2026. The event, to be held online at ...
Alterity Therapeutics Seeks Quotation of ATH Securities in August 2026
Aug 14, 2026
Alterity Therapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission in August 2026, documenting an application for quotation of its securities under the ticker ATH. The filing, signed by Chairman Julian Babarczy on August 14, 2...
Alterity Therapeutics Wins Long-Term U.S. Patent Protection for Lead MSA Drug ATH434
Aug 13, 2026
On August 12, 2026, Alterity Therapeutics announced that the U.S. Patent and Trademark Office granted a new composition of matter patent covering a crystalline mesylate form of its lead asset ATH434, including associated treatment methods for neur...
Alterity Therapeutics Files August 3 Application to Quote ATH Securities
Aug 4, 2026
Alterity Therapeutics Limited, an Australia-based development-stage biopharmaceutical company, operates as a foreign private issuer on U.S. markets and relies on multiple SEC registration statements to support investor access. The company’s ...
Alterity Therapeutics Secures FDA Pathway and Bolsters Funding for ATH434 Phase 3 in MSA
Jul 30, 2026
In the quarter ended 30 June 2026, Alterity Therapeutics secured key regulatory progress for its lead MSA candidate ATH434, with U.S. FDA End-of-Phase 2 meeting minutes confirming a clear registrational pathway. The agency indicated that a single ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.